Trending...
- Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership
- Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders
- Lineus Medical Receives Patent for SafeBreak® Vascular Generation 2
PHILADELPHIA, Nov. 9, 2023 ~ Suvoda LLC, a leading global clinical trial technology company, has successfully conducted usability testing of its electronic clinical outcomes assessment (eCOA) solution in collaboration with RWS Life Sciences. The study resulted in the certification of Suvoda eCOA as highly usable and effective for the patient population.
The findings from the RWS Life Sciences usability testing effort will be presented in a paper titled "Solidifying Usability Testing Guidelines for eCOAs from the Patient Perspective" at ISPOR Europe 2023, to be held in Copenhagen, Denmark, November 12-15. The focus group consisted of oncology patients using smartphone and tablet devices. These patients represented a variety of conditions related to their cancer diagnoses, including difficulties with gripping and reading, as well as concentration and tactile challenges. The study, which included participants ranging from ages 18 to 75, was qualitative in nature and adhered to best practices in user experience research.
More on The PennZone
Chryso Hadjidemetriou, PhD with RWS Life Sciences said "Patient-centered usability testing is valuable because it focuses on whether patients can interact with the eCOA efficiently and effectively, particularly in cases where participants may experience physical or visual accessibility challenges." He further added that "The qualitative and patient-centered process of usability testing helps to measure operational efficacy of the eCOA system; recognize design issues causing patient dissatisfaction and impeding data collection; examine software and working improvements; and understand and evaluate user interaction, with an end-goal of improving the users' experience."
Nearly all participants in the focus group found Suvoda eCOA to be easy to navigate, intuitive, clear, and well-designed. They appreciated the ease of moving through the questionnaire screens, clear instructions, and the flexibility to change answers as needed. Catherine Munera vice president of biometrics for Cara Therapeutics said "Patient-reported outcome (PRO) data is crucial in clinical studies so it's imperative to have data capture tools that are easy for patients to use and manage with minimal intervention from clinical sites." She further added that "Suvoda eCOA was incredibly easy for our patients to use; we had an increase in patient compliance in completing PRO questionnaires as compared to previous studies with other eCOA providers."
More on The PennZone
The usability testing process was conducted in accordance with current industry standards and FDA guidance to ensure the highest level of quality and compliance. Andrés Escallón vice president Suvoda eCOA practice said "Suvoda put the user experience at the center of product development so sites can focus time on patients and not on technology." He further added that "This study validates that our eCOA solution makes it easy and efficient to obtain quality patient outcomes data for submissions and approvals."
Suvoda announced general availability of its eCOA product back in May 2023 which addresses difficulties associated with traditional eCOA products by delivering simplified questionnaire licensing & localizations along with streamlined device logistics. Additionally since Suvoda's solution delivers IRT & Econsent on a single platform it helps improve data integrity & study teams benefit from improved data integrity.
The findings from the RWS Life Sciences usability testing effort will be presented in a paper titled "Solidifying Usability Testing Guidelines for eCOAs from the Patient Perspective" at ISPOR Europe 2023, to be held in Copenhagen, Denmark, November 12-15. The focus group consisted of oncology patients using smartphone and tablet devices. These patients represented a variety of conditions related to their cancer diagnoses, including difficulties with gripping and reading, as well as concentration and tactile challenges. The study, which included participants ranging from ages 18 to 75, was qualitative in nature and adhered to best practices in user experience research.
More on The PennZone
- NEW SEASON OF "The Really Real Estate" APPROVED
- UK Financial Ltd Announces Full Ecosystem To Erc-3643 "SEC-Ready" Tokens For All UK Financial Ltd Tokenized Projects
- Pushing the Wave Series Launches Premium Hardback Editions of 2017–2022 and 2023 Volumes
- ZEELOOL 2025 Black Friday and Cyber Monday Big Deals
- Americans Are Building Family Legacies That Last Generations — Not Just Paychecks That Last a Month
Chryso Hadjidemetriou, PhD with RWS Life Sciences said "Patient-centered usability testing is valuable because it focuses on whether patients can interact with the eCOA efficiently and effectively, particularly in cases where participants may experience physical or visual accessibility challenges." He further added that "The qualitative and patient-centered process of usability testing helps to measure operational efficacy of the eCOA system; recognize design issues causing patient dissatisfaction and impeding data collection; examine software and working improvements; and understand and evaluate user interaction, with an end-goal of improving the users' experience."
Nearly all participants in the focus group found Suvoda eCOA to be easy to navigate, intuitive, clear, and well-designed. They appreciated the ease of moving through the questionnaire screens, clear instructions, and the flexibility to change answers as needed. Catherine Munera vice president of biometrics for Cara Therapeutics said "Patient-reported outcome (PRO) data is crucial in clinical studies so it's imperative to have data capture tools that are easy for patients to use and manage with minimal intervention from clinical sites." She further added that "Suvoda eCOA was incredibly easy for our patients to use; we had an increase in patient compliance in completing PRO questionnaires as compared to previous studies with other eCOA providers."
More on The PennZone
- Bent Danholm Lists Contemporary Lakefront Residence in Winter Garden's Avalon Cove
- Safe Health Zones: A Global Breakthrough to Protect Night-Shift Workers from Preventable Harm
- ProfileSpider Launches Powerful One-Click Profile Scraper for Recruiters and Growth Teams
- NATCO Awarded U.S. Patent for Persimonal® – Breakthrough Innovation in Preparing Persimmon Leaf Extract
- Rio Bela Cosmetics Launches Inclusive Line of Organic Skincare Products
The usability testing process was conducted in accordance with current industry standards and FDA guidance to ensure the highest level of quality and compliance. Andrés Escallón vice president Suvoda eCOA practice said "Suvoda put the user experience at the center of product development so sites can focus time on patients and not on technology." He further added that "This study validates that our eCOA solution makes it easy and efficient to obtain quality patient outcomes data for submissions and approvals."
Suvoda announced general availability of its eCOA product back in May 2023 which addresses difficulties associated with traditional eCOA products by delivering simplified questionnaire licensing & localizations along with streamlined device logistics. Additionally since Suvoda's solution delivers IRT & Econsent on a single platform it helps improve data integrity & study teams benefit from improved data integrity.
Filed Under: Business
0 Comments
Latest on The PennZone
- Own 327 Acres of American Prime Real Estate with 2 Miles Waterfront Worth In Millions for Just $7 — Worldwide Raffle Launched
- Lakefront Acreage in Longwood's Ravensbrook Community Hits the Market
- Monika Balayan Elected Fellow of the Royal Society of Arts (FRSA)
- Best Companies Group Launches Best Companies to Work for in New York Program
- We're Winning: Historic Plunge in Overdose Deaths Marks Stunning Reversal in America's Drug Crisis
- Lineus Medical Receives Patent for SafeBreak® Vascular Generation 2
- IDI Consulting Spreads Holiday Cheer to Families in Need with 11th Annual Toys for Tots Drive
- Escajeda Masonry & Concrete Among Pittsburgh's Fastest-Growing Companies
- New 2025–2026 Energy Rebates: Squeaks Services Explains How to Qualify
- CCHR's New Documentary Prescription for Violence Highlights Overlooked Safety Warnings
- Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership
- Men's Health Network Announces a New Feature to Support the Well-Being of Men When and Where They Are through Text Alerts
- Comp-U-Floor Unveils Powerful New Commercial Module
- Revenue Optics Announces the Appointment of Sonal Chowdhury as Senior Manager – Strategic Operations
- How California Convinces Buyers Not to Purchase New Cars — and How This Hurts Dealers
- Tax Fears and Political Volatility Drive Wealthy UK Residents to Consider Leaving, La Vida Survey Shows
- Titan Steel Buildings Expands Nationwide to Deliver Large Steel Warehouses and Industrial Facilities
- Kaltra Removes Size Barriers for Microchannel Coils with Fully Integrated Large-MCHE Production
- Philadelphia City Council Issues Resolution to Honor Inner Strength Education's 10 Year Anniversary
- Guests Can Save 10 Percent Off New Vacation Rental Homes at KeysCaribbean's Village at Hawks Cay Villas